Document Detail


Novel therapeutic agents under investigation for malignant melanoma.
MedLine Citation:
PMID:  12943498     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malignant melanoma presents a therapeutic challenge. Patients at high risk for recurrence (stage III) are eligible for adjuvant treatment with IFN-alpha or may enrol in a clinical trial. Both options offer no meaningful survival advantage. Patients with metastatic disease (stage IV) have a 5-year survival of < 10% and have no effective treatment options. Despite aggressive investigations into vaccine therapy, no vaccine has yet received FDA approval. Biological therapies with IFN-alpha and IL-2 have demonstrated a real but minimal effect. Chemotherapeutic options are even more dismal. Single-agent chemotherapy yields a 15-20% response rate of short lived duration. Combination chemotherapy alone or with immunological adjuvants yields response rates of 35-45% but with significant toxicity and no significant improvement in survival. Novel treatment agents that target metabolic pathways, angiogenesis inhibitors, antisense therapies, gene therapies and innovative vaccines may offer hope for an otherwise grave disease.
Authors:
Anna C Pavlick; Sylvia Adams; Matthew A Fink; Amanda Bailes
Related Documents :
8180388 - Increased incidence of second neoplasms in patients treated with interferon alpha 2b fo...
10915728 - Interferon beta prevents recurrence of hepatocellular carcinoma after complete resectio...
2222898 - Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal ce...
21078048 - Oncological outcomes after laparoscopic and open radical nephroureterectomy: results fr...
23412768 - The role of para-aortic lymphadenectomy in endometrial cancer.
8180388 - Increased incidence of second neoplasms in patients treated with interferon alpha 2b fo...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  12     ISSN:  1354-3784     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-08-28     Completed Date:  2004-01-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1545-58     Citation Subset:  IM    
Affiliation:
New York University Cancer Institute, 462 First Avenue, BCD 556, New York, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / therapeutic use
Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / therapeutic use
Cancer Vaccines / therapeutic use
Chemotherapy, Adjuvant
Clinical Trials as Topic
Cytokines / metabolism
Enzyme Inhibitors / therapeutic use
Gene Therapy
Humans
Immunotherapy
Melanoma / drug therapy,  secondary,  therapy*
Neoplasm Metastasis
Oligonucleotides, Antisense / therapeutic use
Grant Support
ID/Acronym/Agency:
T32-CA16087/CA/NCI NIH HHS; T32-HL07151/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antineoplastic Agents; 0/Cancer Vaccines; 0/Cytokines; 0/Enzyme Inhibitors; 0/Oligonucleotides, Antisense

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention of perinatal HIV transmission: a review of novel strategies.
Next Document:  Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incont...